Prevalence of cancer and the benign call rate of afirma gene classifier in 18 F-Fluorodeoxyglucose positron emission tomography positive cytologically indeterminate thyroid nodules.

Mayumi EndoJennifer A SiposMatthew D RingelKyle PorterHaikady N NagarajaJohn E PhayLawrence A ShirleyClarine LongChadwick L WrightKatie RollFadi A Nabhan

Published in: Cancer medicine (2021)

The prevalence of cancer/NIFTP in (PET+) ITNs was 28.6-36.4% depending on the method of calculation. The BCR of Afirma GSC was 64%. Combining Afirma GEC/GSC-tested ITNs, BCR was higher in ITNs with a lower risk sonographic pattern.

Keyphrases

positron emission tomography
computed tomography
papillary thyroid
pet ct
acute lymphoblastic leukemia
pet imaging
risk factors
squamous cell
tyrosine kinase
childhood cancer
copy number
chronic myeloid leukemia
gene expression
dna methylation
genome wide identification
monte carlo
optical coherence tomography